Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) – Investment analysts at Lifesci Capital lowered their Q2 2026 earnings per share (EPS) estimates for Sutro Biopharma in a note issued to investors on Friday, May 15th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings of ($1.55) per share for the quarter, down from their previous estimate of ($1.52). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($9.04) per share. Lifesci Capital also issued estimates for Sutro Biopharma’s Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.39) EPS, FY2026 earnings at ($7.76) EPS, Q1 2027 earnings at ($1.48) EPS, Q2 2027 earnings at ($1.54) EPS, Q3 2027 earnings at ($1.64) EPS, Q4 2027 earnings at ($1.47) EPS, FY2027 earnings at ($6.13) EPS and FY2028 earnings at ($6.35) EPS.
Other research analysts have also recently issued research reports about the company. Leerink Partners set a $43.00 price target on Sutro Biopharma and gave the stock an “outperform” rating in a research note on Friday. Wall Street Zen upgraded Sutro Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Mizuho set a $50.00 price target on Sutro Biopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Citigroup restated an “outperform” rating on shares of Sutro Biopharma in a research note on Friday, April 17th. Finally, Citizens Jmp upped their price objective on Sutro Biopharma from $35.00 to $41.00 and gave the company a “market outperform” rating in a research report on Thursday, April 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sutro Biopharma currently has an average rating of “Buy” and a consensus price target of $48.25.
Sutro Biopharma Price Performance
STRO stock opened at $34.48 on Tuesday. Sutro Biopharma has a 1-year low of $6.74 and a 1-year high of $43.85. The business has a fifty day moving average price of $29.43 and a 200-day moving average price of $18.50. The stock has a market capitalization of $571.33 million, a P/E ratio of -2.00 and a beta of 1.63.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.74) by ($0.20). The business had revenue of $14.52 million during the quarter, compared to analyst estimates of $8.89 million.
Institutional Investors Weigh In On Sutro Biopharma
Hedge funds and other institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP purchased a new stake in shares of Sutro Biopharma in the third quarter worth approximately $152,000. ADAR1 Capital Management LLC increased its holdings in Sutro Biopharma by 681.8% during the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock worth $13,064,000 after purchasing an additional 457,364 shares during the period. Cerity Partners LLC increased its holdings in Sutro Biopharma by 169.9% during the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after purchasing an additional 66,372 shares during the period. Qube Research & Technologies Ltd purchased a new position in Sutro Biopharma during the 2nd quarter worth $82,000. Finally, Velan Capital Investment Management LP increased its holdings in Sutro Biopharma by 2.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after purchasing an additional 60,000 shares during the period. 96.99% of the stock is currently owned by hedge funds and other institutional investors.
About Sutro Biopharma
Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.
Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.
Featured Stories
- Five stocks we like better than Sutro Biopharma
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
